Financing channel feed

Armed an­ti­body play­er ADC lands a $105M mega-round to back pipeline con­struc­tion

9 years ago
Startups

Sofinno­va bags $650M for a ded­i­cat­ed biotech fund

9 years ago

Biotechs grabbed $1.83B in VC cash in Q3. Still fast but a lit­tle less fu­ri­ous

9 years ago

Azur­Rx clips its IPO price, but man­ages to get the job done

9 years ago

Helsinn sets up a bou­tique in­vest­ment fund with a rov­ing eye for on­col­o­gy up­starts

9 years ago

Reuters probe spot­lights a con­flict of in­ter­est be­tween biotech in­vestor F-Prime and gi­ant Fi­deli­ty

9 years ago

UK start­up tack­les hot neoanti­gen field in can­cer drugs

9 years ago
Startups

Presto! Wall Street ma­gi­cian Vivek Ra­maswamy has an­oth­er in­stant biotech IPO to sell you

9 years ago
People

Alzheimer’s play­er AC Im­mune taps IPO for $58M raise, sees shares soar

9 years ago

The next check­points? Im­muno-on­col­o­gy up­start looks to find new ways to un­leash T cells

9 years ago
Startups

Out of lim­bo, Sarep­ta is rais­ing $225M and tak­ing bids on a pri­or­i­ty vouch­er as it revs up mar­ket­ing

9 years ago
Pharma

Biotech uni­corn Mod­er­na gam­bles $110M on a ground­break­ing mR­NA man­u­fac­tur­ing fa­cil­i­ty, blue­prints plant #2

9 years ago
R&D

Third Rock ramps up a $57M up­start fo­cus­ing on pro­teins in mo­tion

9 years ago
Startups

Sanofi is team­ing with Ver­i­ly on a $500M JV aimed at mar­ry­ing tech with di­a­betes drugs

9 years ago

De­nali grabs an­oth­er megaround while ink­ing a flur­ry of neu­rode­gen­er­a­tion R&D pacts

9 years ago
Startups

Low-pro­file Thar Phar­ma takes a $50M fli­er on a weak IPO mar­ket

9 years ago

From boom to swoon: Biotech IPOs fade fast in Q2

9 years ago
R&D

Q2 ven­ture in­vest­ing slows a tad, but the big mon­ey still flows in­to biotech

9 years ago
R&D

The biotech IPO feast flags as in­vestors lose their ap­petite for R&D risk

9 years ago

IPO bound? CRISPR Ther­a­peu­tics ups B round to a cool $140M

9 years ago
Pharma

$121M lat­er, Langer-backed Se­lec­ta rais­es $70M more from its IPO

9 years ago

An­ti­fun­gal play­er F2G banks $60M, eyes IPO in lead­up to a PhI­II tri­al

9 years ago
R&D
First page Previous page 142143144145
A service from the Financial Times